- Home
- CEPU vs PVLA Comparison
CEPU vs PVLA Comparison
Compare CEPU & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPU | PVLA |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | Argentina | United States |
| Employees | N/A | 14 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CEPU | PVLA |
|---|---|---|
| Price | $15.09 | $124.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $17.50 | ★ $161.13 |
| AVG Volume (30 Days) | 288.0K | ★ 314.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.76 | N/A |
| Revenue Next Year | $28.12 | N/A |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.43 | $18.23 |
| 52 Week High | $18.50 | $151.18 |
Technical Indicators
Market Signals| Indicator | CEPU | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 54.75 |
| Support Level | $14.88 | $76.95 |
| Resistance Level | $16.60 | $151.18 |
| Average True Range (ATR) | 0.65 | 10.39 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 45.52 | 34.50 |
Price Performance
Historical ComparisonAbout CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.